Effect of Helicobacter Pylori Treatment on Idiopathic Central Serous Chorioretinopathy (ICSCR)

Central Serous Chorioretinopathy Clinical Trial

— ICSCR  

Official title:

Effect of Helicobacter Pylori Treatment on Remission of Idiopathic Central Serous Chorioretinopathy (ICSCR)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00817245
• Other study ID #: 86-47
• Status: Completed
• Phase: Phase 1/Phase 2
• First received: January 1, 2009
• Last updated: January 5, 2009
• Start date: March 2008
• Est. completion date: January 2009

Study information

• Verified date: January 2009
• Source: Tabriz University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Etiology of ICSCR is not known however recent studies regard the role of immunologic and infectious processes in the pathogenesis of ICSCR.one of these hypothesis is the role of helicobacter pylori in the pathogenesis of ICSCR so perhaps treatment of h pylori have positive effect on the remission of ICSCR.

Description:

we will choose 50 cases of patients with ICSCR who are infected with h.pylori.25 cases will receive anti h.pylori regiment and 25 cases as controls will receive no medication.then we will compare the time of submacular fluid resorption and macular thickness and visual acuity among these two groups.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 50
• Est. completion date: January 2009
• Est. primary completion date: October 2008
• Accepts healthy volunteers: No
• Gender: All
• Age group: 28 Years to 40 Years

Eligibility

Inclusion Criteria:

• the persons who are infected with helicobacter pylori and have ICSCR

Exclusion Criteria:

• history of previous eye surgery ,to have indication of laser therapy,corticosteroid therapy,pregnancy,

Related Conditions & MeSH terms

• Central Serous Chorioretinopathy

Intervention

Drug:
• omeprazole, Amoxicillin, metronidazole
we will evaluate the effect of medication(anti h.pylori) on the remission of ICSCR

Locations

Country	Name	City	State
Iran, Islamic Republic of	Alireza JavadzadehTabriz	Tabriz

Sponsors (1)

Lead Sponsor	Collaborator
Tabriz University

Country where clinical trial is conducted

Iran, Islamic Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Subretinal fluid level
Secondary	time of sub macular fluid absorption